A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
This study is ongoing, but not recruiting participants.
Roche Pharma AG
Information provided by (Responsible Party):
First received: May 9, 2008
Last updated: October 3, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Study Completion Date:||No date given|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||March 25, 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011 Nov 19;378(9805):1779-87. doi: 10.1016/S0140-6736(11)61649-8.